Precision BioSciences stock falls out of Nasdaq compliance


A gene editing company in Durham will need to raise its stock price if it wants to stay listed on the Nasdaq.

Previous Analysts 'puzzled' on why Bank of America opted out of bid for First Republic
Next Jefferson Health repurposing Elkins Park hospital, expanding MossRehab